William D. McCombe, Chief Financial Officer of Cytek Biosciences, Inc., filed a Form 4 on November 20, 2026, reporting the vesting of three separate restricted stock unit awards and the withholding of shares to cover tax obligations, all transacted on November 18, 2026.
Key Highlights
- Three RSU tranches vested: McCombe acquired 6,320, 13,051, and 16,049 shares of common stock via RSU conversions on November 18, 2026, according to the filing.
- Tax withholding shares surrendered: The company withheld 2,127, 4,392, and 5,401 shares, respectively, at $5.92 per share to satisfy tax obligations arising from each vesting event.
- Resulting direct ownership: Following all reported transactions, McCombe directly held 158,193 shares of common stock, the filing disclosed.
- Remaining RSU balances: After the vesting events, McCombe retained 37,929, 121,811, and 213,993 RSUs outstanding across the three award series, per the filing.
- Issuer and exchange: Cytek Biosciences, Inc. is listed as NASDAQ:CTKB, as stated on the filing's cover.
McCombe's November 18 RSU Vestings and Share Withholding at Cytek Biosciences
According to the Form 4 filed with the SEC on November 20, 2026, William D. McCombe, Chief Financial Officer of Cytek Biosciences, Inc. (NASDAQ:CTKB), reported six transactions executed on November 18, 2026, all involving restricted stock units. Each of three RSU awards contributed a vested tranche that converted into common shares, followed immediately by a share-withholding transaction tied to tax obligations.
The filing states that McCombe acquired 6,320 shares under the first RSU award (transaction code M), after which 2,127 shares were withheld by the issuer at $5.92 per share (transaction code F) to cover tax withholding, leaving a direct holding of 138,886 shares at that point. A second RSU tranche of 13,051 shares then vested, with 4,392 shares withheld at the same price of $5.92, bringing the running total to 147,545 shares. A third tranche of 16,049 shares vested, with 5,401 shares withheld at $5.92, resulting in a final reported direct holding of 158,193 shares of common stock.
The filing explains that each RSU "represents a contingent right to receive one share of the Issuer's common stock," and that the withheld shares were "surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award." The three RSU awards carry differing four-year vesting schedules. After these transactions, the remaining RSU balances stood at 37,929, 121,811, and 213,993, respectively, all held directly. The form was signed by Wenbin Jiang as attorney-in-fact on November 20, 2026.
What Was Disclosed
The filing reports three RSU vesting events and corresponding tax-related share withholdings by Cytek Biosciences CFO William D. McCombe on November 18, 2026, with a final direct common stock holding of 158,193 shares following all reported transactions.


Please wait processing your request...